X-Cell completes ETHOS II drug-eluting stent trial enrolment
This article was originally published in Clinica
Executive Summary
X-Cell Medical has completed the patient-enrolment phase of its 17(beta)-oestradiol-eluting stent technology for preventing coronary restenosis.